发明授权
US09428464B2 Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
有权
犬奈宁-3-单加氧酶抑制剂，药物组合物及其使用方法
- 专利标题： Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
- 专利标题（中）： 犬奈宁-3-单加氧酶抑制剂，药物组合物及其使用方法
-
申请号： US14241699申请日： 2012-08-28
-
公开(公告)号： US09428464B2公开(公告)日： 2016-08-30
- 发明人: Stephen Martin Courtney , Michael Prime , William Mitchell , Christopher John Brown , Paula C. De Aguiar Pena , Peter Johnson , Celia Dominguez , Leticia M. Toledo-Sherman , Ignacio Muñoz-Sanjuan
- 申请人： Stephen Martin Courtney , Michael Prime , William Mitchell , Christopher John Brown , Paula C. De Aguiar Pena , Peter Johnson , Celia Dominguez , Leticia M. Toledo-Sherman , Ignacio Muñoz-Sanjuan
- 申请人地址： US NY New York
- 专利权人： CHDI Foundation, Inc.
- 当前专利权人： CHDI Foundation, Inc.
- 当前专利权人地址： US NY New York
- 代理机构： Sheppard Mullin Richter & Hampton LLP
- 国际申请： PCT/US2012/052617 WO 20120828
- 国际公布： WO2013/033068 WO 20130307
- 主分类号： C07D239/52
- IPC分类号： C07D239/52 ; A61K31/506 ; C07D239/28 ; C07D403/12 ; C07D403/06 ; C07D405/12 ; C07D413/12 ; C07D491/048 ; C07D239/42 ; C07D401/04 ; C07D401/12 ; C07D417/12 ; C07D471/04 ; C07D487/04
摘要：
Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.